Plain-English translation of NCT07076615 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether dapagliflozin (a medication already used for heart failure) can help hospitalized patients with acute heart failure recover better when given early, along with their standard water-removal medications. Researchers want to see if this medication helps reduce fluid buildup in the lungs, improves how well the standard medications work, and gets patients home from the hospital sooner.
Acute heart failure is a serious condition that sends many people to the hospital, and doctors are still working to find the best ways to help patients recover faster and avoid coming back to the hospital again. This medication has helped people with chronic heart failure, but doctors need to test whether it works just as well when patients are very sick and hospitalized.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either take the new medication once daily by mouth along with your standard IV water-removal medications, or to receive only the standard IV medications alone. During your hospital stay, you will have lung ultrasounds to measure fluid buildup, heart function tests, and blood samples taken within 24 hours of admission and again at discharge to track how well the treatment is working.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Egypt